{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:10:11Z","timestamp":1793398211069,"version":"4.5.0"},"reference-count":224,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82473804"],"award-info":[{"award-number":["No. 82473804"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08312-w","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T10:34:57Z","timestamp":1779705297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mechanisms and reversal strategies of liver fibrosis: from regulation of cell fate to clinical translation"],"prefix":"10.1186","volume":"24","author":[{"given":"Chuhan","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"issue":"16","key":"8312_CR1","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.3748\/wjg.v28.i16.1718","volume":"28","author":"HK Verma","year":"2022","unstructured":"Verma HK, Prasad K, Kumar P, Lvks B. Viral hepatitis: A global burden needs future directions for the management. World J Gastroenterol. 2022;28(16):1718\u201321.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"8312_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151\u201371.","journal-title":"J Hepatol"},{"issue":"1","key":"8312_CR3","doi-asserted-by":"publisher","first-page":"e1499","DOI":"10.1002\/wsbm.1499","volume":"13","author":"J Berumen","year":"2021","unstructured":"Berumen J, Baglieri J, Kisseleva T, Mekeel K. Liver fibrosis: Pathophysiology and clinical implications. WIREs Mech Dis. 2021;13(1):e1499.","journal-title":"WIREs Mech Dis"},{"issue":"7835","key":"8312_CR4","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","volume":"587","author":"NC Henderson","year":"2020","unstructured":"Henderson NC, Rieder F, Wynn TA. Fibrosis: from mechanisms to medicines. Nature. 2020;587(7835):555\u201366.","journal-title":"Nature"},{"issue":"3","key":"8312_CR5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/JCI30542","volume":"117","author":"JP Iredale","year":"2007","unstructured":"Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest. 2007;117(3):539\u201348.","journal-title":"J Clin Invest"},{"issue":"4","key":"8312_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3350\/cmh.2017.0078","volume":"23","author":"RC Lo","year":"2017","unstructured":"Lo RC, Kim H. Histopathological evaluation of liver fibrosis and cirrhosis regression. Clin Mol Hepatol. 2017;23(4):302\u20137.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"8312_CR7","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1053\/j.gastro.2012.06.036","volume":"143","author":"JS Troeger","year":"2012","unstructured":"Troeger JS, Mederacke I, Gwak GY, Dapito DH, Mu X, Hsu CC, Pradere JP, Friedman RA, Schwabe RF. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology. 2012;143(4):1073\u2013e10831022.","journal-title":"Gastroenterology"},{"issue":"24","key":"8312_CR8","doi-asserted-by":"publisher","first-page":"9448","DOI":"10.1073\/pnas.1201840109","volume":"109","author":"T Kisseleva","year":"2012","unstructured":"Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, Iwaisako K, Moore-Morris T, Scott B, Tsukamoto H, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A. 2012;109(24):9448\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8312_CR9","doi-asserted-by":"crossref","unstructured":"Cerrito L, Galasso L, Iaccarino J, Pizzi A, Termite F, Esposto G, Borriello R, Ainora ME, Gasbarrini A, Zocco MA. Present and future perspectives in the treatment of liver fibrosis. Pharmaceuticals (Basel). 2025;18(9).","DOI":"10.3390\/ph18091321"},{"key":"8312_CR10","doi-asserted-by":"crossref","unstructured":"Roehlen N, Crouchet E, Baumert TF. Liv\ttives. Cells 2020, 9(4).","DOI":"10.3390\/cells9040875"},{"issue":"3","key":"8312_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18(3):151\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8312_CR12","doi-asserted-by":"publisher","first-page":"766855","DOI":"10.3389\/fmolb.2021.766855","volume":"8","author":"J Zhang","year":"2021","unstructured":"Zhang J, Liu Q, He J, Li Y. Novel Therapeutic Targets in Liver Fibrosis. Front Mol Biosci. 2021;8:766855.","journal-title":"Front Mol Biosci"},{"key":"8312_CR13","doi-asserted-by":"crossref","unstructured":"Pei Q, Yi Q, Tang L. Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities. Int J Mol Sci 2023, 24(11).","DOI":"10.3390\/ijms24119671"},{"key":"8312_CR14","doi-asserted-by":"crossref","unstructured":"Yan T, Yan N, Xia Y, Sawaswong V, Zhu X, Dias HB, Aibara D, Takahashi S, Hamada K, Saito Y, et al. Hepatocyte-specific CCAAT\/enhancer binding protein \u03b1 restricts liver fibrosis progression. J Clin Invest 2024, 134(7).","DOI":"10.1172\/JCI166731"},{"issue":"4","key":"8312_CR15","doi-asserted-by":"publisher","first-page":"e34945","DOI":"10.1371\/journal.pone.0034945","volume":"7","author":"N Testerink","year":"2012","unstructured":"Testerink N, Ajat M, Houweling M, Brouwers JF, Pully VV, van Manen HJ, Otto C, Helms JB, Vaandrager AB. Replacement of retinyl esters by polyunsaturated triacylglycerol species in lipid droplets of hepatic stellate cells during activation. PLoS ONE. 2012;7(4):e34945.","journal-title":"PLoS ONE"},{"key":"8312_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","volume":"12","author":"S Affo","year":"2017","unstructured":"Affo S, Yu LX, Schwabe RF. The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. Annu Rev Pathol. 2017;12:153\u201386.","journal-title":"Annu Rev Pathol"},{"key":"8312_CR17","doi-asserted-by":"publisher","first-page":"591393","DOI":"10.3389\/fphar.2020.591393","volume":"11","author":"N Ding","year":"2020","unstructured":"Ding N, Wei B, Fu X, Wang C, Wu Y. Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis. Front Pharmacol. 2020;11:591393.","journal-title":"Front Pharmacol"},{"key":"8312_CR18","doi-asserted-by":"publisher","first-page":"100224","DOI":"10.1016\/j.aohep.2020.06.010","volume":"21","author":"J Zhao","year":"2021","unstructured":"Zhao J, Qi YF, Yu YR. STAT3: A key regulator in liver fibrosis. Ann Hepatol. 2021;21:100224.","journal-title":"Ann Hepatol"},{"key":"8312_CR19","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1038\/ncomms3823","volume":"4","author":"I Mederacke","year":"2013","unstructured":"Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, Pradere JP, Schwabe RF. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823.","journal-title":"Nat Commun"},{"issue":"9","key":"8312_CR20","doi-asserted-by":"publisher","first-page":"42394","DOI":"10.31083\/FBL42394","volume":"30","author":"X Wang","year":"2025","unstructured":"Wang X, Wang Y, Yang M, Zhao T, Feng Z, Zhou Y, Li X, Yang Y, Liu Z, Zheng G, et al. Single-cell Transcriptome Analysis Reveals the Potential Role of Hepatic Stellate Cells in Liver Fibrosis. Front Biosci (Landmark Ed). 2025;30(9):42394.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"32","key":"8312_CR21","doi-asserted-by":"publisher","first-page":"E3297","DOI":"10.1073\/pnas.1400062111","volume":"111","author":"K Iwaisako","year":"2014","unstructured":"Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ, Liu X, Xu J, Wang P, Paik YH, et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A. 2014;111(32):E3297\u20133305.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8312_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1055\/s-0031-1272832","volume":"31","author":"L Fabris","year":"2011","unstructured":"Fabris L, Strazzabosco M. Epithelial-mesenchymal interactions in biliary diseases. Semin Liver Dis. 2011;31(1):11\u201332.","journal-title":"Semin Liver Dis"},{"issue":"4","key":"8312_CR23","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/hep.22193","volume":"47","author":"RG Wells","year":"2008","unstructured":"Wells RG. The role of matrix stiffness in regulating cell behavior. Hepatology. 2008;47(4):1394\u2013400.","journal-title":"Hepatology"},{"issue":"11","key":"8312_CR24","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","volume":"34","author":"H Tilg","year":"2022","unstructured":"Tilg H, Adolph TE, Trauner M. Gut-liver axis: Pathophysiological concepts and clinical implications. Cell Metab. 2022;34(11):1700\u201318.","journal-title":"Cell Metab"},{"issue":"2","key":"8312_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3181\/0707-MR-190","volume":"233","author":"T Kisseleva","year":"2008","unstructured":"Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood). 2008;233(2):109\u201322.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"8312_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1172\/JCI200522675","volume":"115","author":"JS Duffield","year":"2005","unstructured":"Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, Lang R, Iredale JP. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest. 2005;115(1):56\u201365.","journal-title":"J Clin Invest"},{"issue":"1","key":"8312_CR27","doi-asserted-by":"publisher","first-page":"G200","DOI":"10.1152\/ajpgi.2001.281.1.G200","volume":"281","author":"CA Rivera","year":"2001","unstructured":"Rivera CA, Bradford BU, Hunt KJ, Adachi Y, Schrum LW, Koop DR, Burchardt ER, Rippe RA, Thurman RG. Attenuation of CCl(4)-induced hepatic fibrosis by GdCl(3) treatment or dietary glycine. Am J Physiol Gastrointest Liver Physiol. 2001;281(1):G200\u2013207.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"7783","key":"8312_CR28","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","volume":"575","author":"P Ramachandran","year":"2019","unstructured":"Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT, Portman JR, Matchett KP, Brice M, Marwick JA, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature. 2019;575(7783):512\u20138.","journal-title":"Nature"},{"issue":"2","key":"8312_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209\u201318.","journal-title":"J Clin Invest"},{"key":"8312_CR30","doi-asserted-by":"crossref","unstructured":"Zhang D, Zhang Y, Sun B. The molecular mechanisms of liver fibrosis and its potential therapy in application. Int J Mol Sci 2022, 23(20).","DOI":"10.3390\/ijms232012572"},{"issue":"1 Suppl","key":"8312_CR31","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","volume":"62","author":"C Trautwein","year":"2015","unstructured":"Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: Concept to treatment. J Hepatol. 2015;62(1 Suppl):S15\u201324.","journal-title":"J Hepatol"},{"issue":"5","key":"8312_CR32","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","volume":"64","author":"YA Lee","year":"2015","unstructured":"Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64(5):830\u201341.","journal-title":"Gut"},{"issue":"3","key":"8312_CR33","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/hep.27332","volume":"61","author":"E Seki","year":"2015","unstructured":"Seki E, Schwabe RF. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology. 2015;61(3):1066\u201379.","journal-title":"Hepatology"},{"issue":"5","key":"8312_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jcmgh.2015.06.011","volume":"1","author":"C Bocca","year":"2015","unstructured":"Bocca C, Novo E, Miglietta A, Parola M. Angiogenesis and Fibrogenesis in Chronic Liver Diseases. Cell Mol Gastroenterol Hepatol. 2015;1(5):477\u201388.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"2","key":"8312_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1055\/s-0035-1550061","volume":"35","author":"RG Wells","year":"2015","unstructured":"Wells RG, Schwabe RF. Origin and function of myofibroblasts in the liver. Semin Liver Dis. 2015;35(2):97\u2013106.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"8312_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"TA Wynn","year":"2008","unstructured":"Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199\u2013210.","journal-title":"J Pathol"},{"issue":"7321","key":"8312_CR37","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nature09493","volume":"468","author":"BS Ding","year":"2010","unstructured":"Ding BS, Nolan DJ, Butler JM, James D, Babazadeh AO, Rosenwaks Z, Mittal V, Kobayashi H, Shido K, Lyden D, et al. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature. 2010;468(7321):310\u20135.","journal-title":"Nature"},{"issue":"4","key":"8312_CR38","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1053\/j.gastro.2011.12.017","volume":"142","author":"G Xie","year":"2012","unstructured":"Xie G, Wang X, Wang L, Wang L, Atkinson RD, Kanel GC, Gaarde WA, Deleve LD. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Gastroenterology. 2012;142(4):918\u2013e927916.","journal-title":"Gastroenterology"},{"issue":"3","key":"8312_CR39","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/hep.22351","volume":"48","author":"LD Deleve","year":"2008","unstructured":"Deleve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology. 2008;48(3):920\u201330.","journal-title":"Hepatology"},{"issue":"3","key":"8312_CR40","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/hep.30227","volume":"69","author":"AC Maretti-Mira","year":"2019","unstructured":"Maretti-Mira AC, Wang X, Wang L, DeLeve LD. Incomplete Differentiation of Engrafted Bone Marrow Endothelial Progenitor Cells Initiates Hepatic Fibrosis in the Rat. Hepatology. 2019;69(3):1259\u201372.","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"8312_CR41","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1440-1746.2010.06592.x","volume":"26","author":"H Jaeschke","year":"2011","unstructured":"Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury: Present concepts. J Gastroenterol Hepatol. 2011;26(Suppl 1):173\u20139.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"8312_CR42","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1182\/bloodadvances.2017010868","volume":"2","author":"S Ghafoory","year":"2018","unstructured":"Ghafoory S, Varshney R, Robison T, Kouzbari K, Woolington S, Murphy B, Xia L, Ahamed J. Platelet TGF-\u03b21 deficiency decreases liver fibrosis in a mouse model of liver injury. Blood Adv. 2018;2(5):470\u201380.","journal-title":"Blood Adv"},{"key":"8312_CR43","doi-asserted-by":"crossref","unstructured":"Derynck R, Budi EH. Specificity, versatility, and control of TGF-\u03b2 family signaling. Sci Signal 2019, 12(570).","DOI":"10.1126\/scisignal.aav5183"},{"issue":"1","key":"8312_CR44","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jhep.2024.07.034","volume":"82","author":"E Crouchet","year":"2025","unstructured":"Crouchet E, Dachraoui M, J\u00fchling F, Roehlen N, Oudot MA, Durand SC, Ponsolles C, Gadenne C, Meiss-Heydmann L, Moehlin J, et al. Targeting the liver clock improves fibrosis by restoring TGF-\u03b2 signaling. J Hepatol. 2025;82(1):120\u201333.","journal-title":"J Hepatol"},{"key":"8312_CR45","doi-asserted-by":"publisher","first-page":"787748","DOI":"10.3389\/fphar.2022.787748","volume":"13","author":"FD Wang","year":"2022","unstructured":"Wang FD, Zhou J, Chen EQ. Molecular Mechanisms and Potential New Therapeutic Drugs for Liver Fibrosis. Front Pharmacol. 2022;13:787748.","journal-title":"Front Pharmacol"},{"issue":"4","key":"8312_CR46","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1152\/physrev.1999.79.4.1283","volume":"79","author":"CH Heldin","year":"1999","unstructured":"Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79(4):1283\u2013316.","journal-title":"Physiol Rev"},{"key":"8312_CR47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.cytogfr.2015.10.002","volume":"28","author":"E Borkham-Kamphorst","year":"2016","unstructured":"Borkham-Kamphorst E, Weiskirchen R. The PDGF system and its antagonists in liver fibrosis. Cytokine Growth Factor Rev. 2016;28:53\u201361.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5","key":"8312_CR48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cyto.2005.06.005","volume":"31","author":"K Breitkopf","year":"2005","unstructured":"Breitkopf K, Roeyen C, Sawitza I, Wickert L, Floege J, Gressner AM. Expression patterns of PDGF-A, -B, -C and -D and the PDGF-receptors alpha and beta in activated rat hepatic stellate cells (HSC). Cytokine. 2005;31(5):349\u201357.","journal-title":"Cytokine"},{"issue":"3","key":"8312_CR49","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jhep.2006.04.010","volume":"45","author":"P Czochra","year":"2006","unstructured":"Czochra P, Klopcic B, Meyer E, Herkel J, Garcia-Lazaro JF, Thieringer F, Schirmacher P, Biesterfeld S, Galle PR, Lohse AW, et al. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol. 2006;45(3):419\u201328.","journal-title":"J Hepatol"},{"issue":"9","key":"8312_CR50","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1073\/pnas.0409722102","volume":"102","author":"JS Campbell","year":"2005","unstructured":"Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, Odell MM, Bauer RL, Ren HP, Haugen HS, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2005;102(9):3389\u201394.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"8312_CR51","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1111\/acer.12167","volume":"37","author":"R Shah","year":"2013","unstructured":"Shah R, Reyes-Gordillo K, Arellanes-Robledo J, Lechuga CG, Hern\u00e1ndez-Nazara Z, Cotty A, Rojkind M, Lakshman MR. TGF-\u03b21 up-regulates the expression of PDGF-\u03b2 receptor mRNA and induces a delayed PI3K-, AKT-, and p70(S6K) -dependent proliferative response in activated hepatic stellate cells. Alcohol Clin Exp Res. 2013;37(11):1838\u201348.","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"8312_CR52","doi-asserted-by":"publisher","first-page":"e92925","DOI":"10.1371\/journal.pone.0092925","volume":"9","author":"BJ Hayes","year":"2014","unstructured":"Hayes BJ, Riehle KJ, Shimizu-Albergine M, Bauer RL, Hudkins KL, Johansson F, Yeh MM, Mahoney WM Jr., Yeung RS, Campbell JS. Activation of platelet-derived growth factor receptor alpha contributes to liver fibrosis. PLoS ONE. 2014;9(3):e92925.","journal-title":"PLoS ONE"},{"key":"8312_CR53","doi-asserted-by":"publisher","first-page":"155380","DOI":"10.1016\/j.metabol.2022.155380","volume":"140","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wang P, Yu Y, Huang E, Yao Y, Guo D, Peng H, Tian B, Zheng Q, Jia M, et al. Hepatocyte Ninjurin2 promotes hepatic stellate cell activation and liver fibrosis through the IGF1R\/EGR1\/PDGF-BB signaling pathway. Metabolism. 2023;140:155380.","journal-title":"Metabolism"},{"issue":"6","key":"8312_CR54","first-page":"960","volume":"9","author":"K Duspara","year":"2021","unstructured":"Duspara K, Bojanic K, Pejic JI, Kuna L, Kolaric TO, Nincevic V, Smolic R, Vcev A, Glasnovic M, Curcic IB, et al. Targeting the Wnt Signaling Pathway in Liver Fibrosis for Drug Options: An Update. J Clin Transl Hepatol. 2021;9(6):960\u201371.","journal-title":"J Clin Transl Hepatol"},{"key":"8312_CR55","doi-asserted-by":"publisher","first-page":"1517226","DOI":"10.3389\/fonc.2024.1517226","volume":"14","author":"G Dai","year":"2024","unstructured":"Dai G, Lin J, Jiang Y, Liu X, Chen P, Zhang Y, Song Z, Zhuang X, Cong J, Li Y, et al. Aurora kinase A promotes hepatic stellate cell activation and liver fibrosis through the Wnt\/\u03b2-catenin pathway. Front Oncol. 2024;14:1517226.","journal-title":"Front Oncol"},{"issue":"1","key":"8312_CR56","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13287-022-02906-z","volume":"13","author":"QW Liu","year":"2022","unstructured":"Liu QW, Ying YM, Zhou JX, Zhang WJ, Liu ZX, Jia BB, Gu HC, Zhao CY, Guan XH, Deng KY, et al. Human amniotic mesenchymal stem cells-derived IGFBP-3, DKK-3, and DKK-1 attenuate liver fibrosis through inhibiting hepatic stellate cell activation by blocking Wnt\/\u03b2-catenin signaling pathway in mice. Stem Cell Res Ther. 2022;13(1):224.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"8312_CR57","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0009-9120(01)00210-7","volume":"34","author":"PM Jacobson Brown","year":"2001","unstructured":"Jacobson Brown PM, Neuman MG. Immunopathogenesis of hepatitis C viral infection: Th1\/Th2 responses and the role of cytokines. Clin Biochem. 2001;34(3):167\u201371.","journal-title":"Clin Biochem"},{"issue":"3","key":"8312_CR58","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jhep.2014.04.026","volume":"61","author":"A Boltjes","year":"2014","unstructured":"Boltjes A, Movita D, Boonstra A, Woltman AM. The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J Hepatol. 2014;61(3):660\u201371.","journal-title":"J Hepatol"},{"issue":"7","key":"8312_CR59","doi-asserted-by":"publisher","first-page":"e0219508","DOI":"10.1371\/journal.pone.0219508","volume":"14","author":"D Baskic","year":"2019","unstructured":"Baskic D, Vukovic V, Popovic S, Jovanovic D, Mitrovic S, Djurdjevic P, Avramovic D, Arsovic A, Bankovic D, Cukic J, et al. Chronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution. PLoS ONE. 2019;14(7):e0219508.","journal-title":"PLoS ONE"},{"issue":"2","key":"8312_CR60","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1053\/j.gastro.2003.11.018","volume":"126","author":"R Bataller","year":"2004","unstructured":"Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology. 2004;126(2):529\u201340.","journal-title":"Gastroenterology"},{"issue":"12","key":"8312_CR61","doi-asserted-by":"publisher","first-page":"11329","DOI":"10.1074\/jbc.M410161200","volume":"280","author":"A Mazzocca","year":"2005","unstructured":"Mazzocca A, Sciammetta SC, Carloni V, Cosmi L, Annunziato F, Harada T, Abrignani S, Pinzani M. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem. 2005;280(12):11329\u201339.","journal-title":"J Biol Chem"},{"key":"8312_CR62","doi-asserted-by":"publisher","first-page":"37717","DOI":"10.1038\/srep37717","volume":"6","author":"J Gong","year":"2016","unstructured":"Gong J, Tu W, Han J, He J, Liu J, Han P, Wang Y, Li M, Liu M, Liao J, et al. Hepatic SATB1 induces paracrine activation of hepatic stellate cells and is upregulated by HBx. Sci Rep. 2016;6:37717.","journal-title":"Sci Rep"},{"issue":"4","key":"8312_CR63","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.4049\/jimmunol.1203013","volume":"191","author":"Z Tan","year":"2013","unstructured":"Tan Z, Qian X, Jiang R, Liu Q, Wang Y, Chen C, Wang X, Ryffel B, Sun B. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol. 2013;191(4):1835\u201344.","journal-title":"J Immunol"},{"issue":"1","key":"8312_CR64","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12967-017-1167-y","volume":"15","author":"X Li","year":"2017","unstructured":"Li X, Su Y, Hua X, Xie C, Liu J, Huang Y, Zhou L, Zhang M, Li X, Gao Z. Levels of hepatic Th17 cells and regulatory T cells upregulated by hepatic stellate cells in advanced HBV-related liver fibrosis. J Transl Med. 2017;15(1):75.","journal-title":"J Transl Med"},{"issue":"2","key":"8312_CR65","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/jat.1393","volume":"29","author":"P Muriel","year":"2009","unstructured":"Muriel P. NF-kappaB in liver diseases: a target for drug therapy. J Appl Toxicol. 2009;29(2):91\u2013100.","journal-title":"J Appl Toxicol"},{"issue":"1","key":"8312_CR66","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jcmgh.2017.04.007","volume":"4","author":"E Moran-Salvador","year":"2017","unstructured":"Moran-Salvador E, Mann J. Epigenetics and Liver Fibrosis. Cell Mol Gastroenterol Hepatol. 2017;4(1):125\u201334.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"8","key":"8312_CR67","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1053\/j.gastro.2019.02.038","volume":"156","author":"N Hamdane","year":"2019","unstructured":"Hamdane N, J\u00fchling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, et al. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response. Gastroenterology. 2019;156(8):2313\u2013e23292317.","journal-title":"Gastroenterology"},{"issue":"6","key":"8312_CR68","doi-asserted-by":"publisher","first-page":"e1008181","DOI":"10.1371\/journal.pgen.1008181","volume":"15","author":"S Perez","year":"2019","unstructured":"Perez S, Kaspi A, Domovitz T, Davidovich A, Lavi-Itzkovitz A, Meirson T, Alison Holmes J, Dai CY, Huang CF, Chung RT, et al. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genet. 2019;15(6):e1008181.","journal-title":"PLoS Genet"},{"key":"8312_CR69","doi-asserted-by":"crossref","unstructured":"Zazueta A, Valenzuela-P\u00e9rez L, Ortiz-L\u00f3pez N, Pinto-Le\u00f3n A, Torres V, Gui\u00f1ez D, Aliaga N, Merino P, Sandoval A, Covarrubias N, et al. Alteration of gut microbiota composition in the progression of liver damage in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Int J Mol Sci 2024, 25(8).","DOI":"10.3390\/ijms25084387"},{"issue":"6","key":"8312_CR70","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1002\/hep.32776","volume":"77","author":"J Knorr","year":"2023","unstructured":"Knorr J, Kaufmann B, Inzaugarat ME, Holtmann TM, Geisler L, Hundertmark J, Kohlhepp MS, Boosheri LM, Chilin-Fuentes DR, Birmingham A, et al. Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Hepatology. 2023;77(6):1968\u201382.","journal-title":"Hepatology"},{"issue":"5","key":"8312_CR71","doi-asserted-by":"publisher","first-page":"8591","DOI":"10.3390\/ijms15058591","volume":"15","author":"W Peverill","year":"2014","unstructured":"Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014;15(5):8591\u2013638.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"8312_CR72","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2468-1253(16)30011-5","volume":"1","author":"VW Wong","year":"2016","unstructured":"Wong VW, Chitturi S, Wong GL, Yu J, Chan HL, Farrell GC. Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol. 2016;1(1):56\u201367.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"8312_CR73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/jgh.15746","volume":"37","author":"M Li","year":"2022","unstructured":"Li M, Rajani C, Zheng X, Jia W. The microbial metabolome in metabolic-associated fatty liver disease. J Gastroenterol Hepatol. 2022;37(1):15\u201323.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"8312_CR74","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1053\/jhep.2001.21900","volume":"33","author":"S Sell","year":"2001","unstructured":"Sell S. Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology. 2001;33(3):738\u201350.","journal-title":"Hepatology"},{"issue":"6","key":"8312_CR75","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/hep.20130","volume":"39","author":"TA Roskams","year":"2004","unstructured":"Roskams TA, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P, Brunt EM, Crawford JM, Crosby HA, Desmet V, et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology. 2004;39(6):1739\u201345.","journal-title":"Hepatology"},{"issue":"8","key":"8312_CR76","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/j.1478-3231.2008.01825.x","volume":"28","author":"G Svegliati-Baroni","year":"2008","unstructured":"Svegliati-Baroni G, De Minicis S, Marzioni M. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Liver Int. 2008;28(8):1052\u201364.","journal-title":"Liver Int"},{"issue":"7","key":"8312_CR77","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999\u20132014. e1991.","journal-title":"Gastroenterology"},{"issue":"10","key":"8312_CR78","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1136\/gutjnl-2020-322509","volume":"70","author":"EH Koh","year":"2021","unstructured":"Koh EH, Yoon JE, Ko MS, Leem J, Yun JY, Hong CH, Cho YK, Lee SE, Jang JE, Baek JY, et al. Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis. Gut. 2021;70(10):1954\u201364.","journal-title":"Gut"},{"issue":"12","key":"8312_CR79","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1136\/gutjnl-2021-325013","volume":"71","author":"MU Latif","year":"2022","unstructured":"Latif MU, Schmidt GE, Mercan S, Rahman R, Gibhardt CS, Stejerean-Todoran I, Reutlinger K, Hessmann E, Singh SK, Moeed A, et al. NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression. Gut. 2022;71(12):2561\u201373.","journal-title":"Gut"},{"key":"8312_CR80","doi-asserted-by":"crossref","unstructured":"Asimakopoulou A, Engel KM, Gassler N, Bracht T, Sitek B, Buhl EM, Kalampoka S, Pino\u00e9-Schmidt M, van Helden J, Schiller J, et al. Deletion of perilipin 5 protects against hepatic injury in nonalcoholic fatty liver disease via missing inflammasome activation. Cells 2020, 9(6).","DOI":"10.3390\/cells9061346"},{"issue":"1","key":"8312_CR81","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1038\/s41467-024-48954-2","volume":"15","author":"J Xia","year":"2024","unstructured":"Xia J, Chen H, Wang X, Chen W, Lin J, Xu F, Nie Q, Ye C, Zhong B, Zhao M, et al. Sphingosine d18:1 promotes nonalcoholic steatohepatitis by inhibiting macrophage HIF-2\u03b1. Nat Commun. 2024;15(1):4755.","journal-title":"Nat Commun"},{"issue":"2","key":"8312_CR82","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/hep.20798","volume":"42","author":"G Svegliati-Baroni","year":"2005","unstructured":"Svegliati-Baroni G, Inagaki Y, Rincon-Sanchez AR, Else C, Saccomanno S, Benedetti A, Ramirez F, Rojkind M. Early response of alpha2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-beta independent. Hepatology. 2005;42(2):343\u201352.","journal-title":"Hepatology"},{"issue":"1","key":"8312_CR83","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/hep.510310118","volume":"31","author":"P Greenwel","year":"2000","unstructured":"Greenwel P, Dom\u00ednguez-Rosales JA, Mavi G, Rivas-Estilla AM, Rojkind M. Hydrogen peroxide: a link between acetaldehyde-elicited alpha1(I) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells. Hepatology. 2000;31(1):109\u201316.","journal-title":"Hepatology"},{"issue":"12","key":"8312_CR84","doi-asserted-by":"publisher","first-page":"9853","DOI":"10.1074\/jbc.M110506200","volume":"277","author":"N Nieto","year":"2002","unstructured":"Nieto N, Friedman SL, Cederbaum AI. Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. J Biol Chem. 2002;277(12):9853\u201364.","journal-title":"J Biol Chem"},{"issue":"2","key":"8312_CR85","doi-asserted-by":"publisher","first-page":"100220","DOI":"10.1016\/j.jhepr.2020.100220","volume":"3","author":"B Fairfield","year":"2021","unstructured":"Fairfield B, Schnabl B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep. 2021;3(2):100220.","journal-title":"JHEP Rep"},{"issue":"7245","key":"8312_CR86","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature07965","volume":"459","author":"O Gross","year":"2009","unstructured":"Gross O, Poeck H, Bscheider M, Dostert C, Hannesschl\u00e4ger N, Endres S, Hartmann G, Tardivel A, Schweighoffer E, Tybulewicz V, et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature. 2009;459(7245):433\u20136.","journal-title":"Nature"},{"issue":"4","key":"8312_CR87","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/gutjnl-2017-315123","volume":"68","author":"MJ Heo","year":"2019","unstructured":"Heo MJ, Kim TH, You JS, Blaya D, Sancho-Bru P, Kim SG. Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression. Gut. 2019;68(4):708\u201320.","journal-title":"Gut"},{"issue":"4","key":"8312_CR88","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/hep.28680","volume":"64","author":"TN Bukong","year":"2016","unstructured":"Bukong TN, Iracheta-Vellve A, Saha B, Ambade A, Satishchandran A, Gyongyosi B, Lowe P, Catalano D, Kodys K, Szabo G. Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease. Hepatology. 2016;64(4):1057\u201371.","journal-title":"Hepatology"},{"issue":"2","key":"8312_CR89","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1053\/j.gastro.2005.10.055","volume":"130","author":"S Radaeva","year":"2006","unstructured":"Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology. 2006;130(2):435\u201352.","journal-title":"Gastroenterology"},{"issue":"1","key":"8312_CR90","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1172\/JCI200523928","volume":"115","author":"SL Friedman","year":"2005","unstructured":"Friedman SL. Mac the knife? Macrophages- the double-edged sword of hepatic fibrosis. J Clin Invest. 2005;115(1):29\u201332.","journal-title":"J Clin Invest"},{"issue":"16","key":"8312_CR91","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.7150\/ijbs.49535","volume":"16","author":"R Ren","year":"2020","unstructured":"Ren R, Wang Z, Wu M, Wang H. Emerging Roles of SIRT1 in Alcoholic Liver Disease. Int J Biol Sci. 2020;16(16):3174\u201383.","journal-title":"Int J Biol Sci"},{"issue":"10","key":"8312_CR92","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1172\/JCI60777","volume":"122","author":"J Petrasek","year":"2012","unstructured":"Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, Barrieau M, Min SY, Kurt-Jones EA, Szabo G. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest. 2012;122(10):3476\u201389.","journal-title":"J Clin Invest"},{"issue":"2","key":"8312_CR93","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s10753-021-01571-3","volume":"45","author":"DK Dwivedi","year":"2022","unstructured":"Dwivedi DK, Jena GB. Simultaneous Modulation of NLRP3 Inflammasome and Nrf2\/ARE Pathway Rescues Thioacetamide-Induced Hepatic Damage in Mice: Role of Oxidative Stress and Inflammation. Inflammation. 2022;45(2):610\u201326.","journal-title":"Inflammation"},{"key":"8312_CR94","doi-asserted-by":"publisher","first-page":"152840","DOI":"10.1016\/j.tox.2021.152840","volume":"458","author":"D Ezhilarasan","year":"2021","unstructured":"Ezhilarasan D. Hepatotoxic potentials of methotrexate: Understanding the possible toxicological molecular mechanisms. Toxicology. 2021;458:152840.","journal-title":"Toxicology"},{"key":"8312_CR95","doi-asserted-by":"crossref","unstructured":"Sirbe C, Simu G, Szabo I, Grama A, Pop TL. Pathogenesis of autoimmune hepatitis-cellular and molecular mechanisms. Int J Mol Sci 2021, 22(24).","DOI":"10.3390\/ijms222413578"},{"issue":"Suppl 1","key":"8312_CR96","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1038\/modpathol.3800684","volume":"20","author":"MK Washington","year":"2007","unstructured":"Washington MK. Autoimmune liver disease: overlap and outliers. Mod Pathol. 2007;20(Suppl 1):S15\u201330.","journal-title":"Mod Pathol"},{"key":"8312_CR97","doi-asserted-by":"crossref","unstructured":"Park JW, Kim JH, Kim SE, Jung JH, Jang MK, Park SH, Lee MS, Kim HS, Suk KT, Kim DJ. Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics. Biomedicines 2022, 10(6).","DOI":"10.3390\/biomedicines10061288"},{"issue":"11","key":"8312_CR98","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/nm1663","volume":"13","author":"E Seki","year":"2007","unstructured":"Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007;13(11):1324\u201332.","journal-title":"Nat Med"},{"issue":"10215","key":"8312_CR99","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184\u201396.","journal-title":"Lancet"},{"issue":"4","key":"8312_CR100","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S1665-2681(19)31740-5","volume":"8","author":"P Ramachandran","year":"2009","unstructured":"Ramachandran P, Iredale JP. Reversibility of liver fibrosis. Ann Hepatol. 2009;8(4):283\u201391.","journal-title":"Ann Hepatol"},{"issue":"1","key":"8312_CR101","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1053\/jhep.2001.25349","volume":"34","author":"B Schnabl","year":"2001","unstructured":"Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology. 2001;34(1):89\u2013100.","journal-title":"Hepatology"},{"issue":"3","key":"8312_CR102","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1172\/JCI1018","volume":"102","author":"JP Iredale","year":"1998","unstructured":"Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, Hovell C, Arthur MJ. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 1998;102(3):538\u201349.","journal-title":"J Clin Invest"},{"issue":"4","key":"8312_CR103","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/gut.48.4.548","volume":"48","author":"R Issa","year":"2001","unstructured":"Issa R, Williams E, Trim N, Kendall T, Arthur MJ, Reichen J, Benyon RC, Iredale JP. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut. 2001;48(4):548\u201357.","journal-title":"Gut"},{"issue":"4","key":"8312_CR104","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2008.06.049","volume":"134","author":"V Krizhanovsky","year":"2008","unstructured":"Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, Yee H, Zender L, Lowe SW. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008;134(4):657\u201367.","journal-title":"Cell"},{"issue":"4","key":"8312_CR105","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959\u201374.","journal-title":"J Hepatol"},{"issue":"Suppl 3","key":"8312_CR106","first-page":"S84","volume":"21","author":"T Kisseleva","year":"2006","unstructured":"Kisseleva T, Brenner DA. Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol. 2006;21(Suppl 3):S84\u201387.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5415","key":"8312_CR107","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.284.5415.770","volume":"284","author":"S Artavanis-Tsakonas","year":"1999","unstructured":"Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284(5415):770\u20136.","journal-title":"Science"},{"issue":"3","key":"8312_CR108","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1053\/jhep.2003.50097","volume":"37","author":"B Schnabl","year":"2003","unstructured":"Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner D. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology. 2003;37(3):653\u201364.","journal-title":"Hepatology"},{"issue":"3","key":"8312_CR109","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1189\/JLB.0309135","volume":"86","author":"B Gao","year":"2009","unstructured":"Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol. 2009;86(3):513\u201328.","journal-title":"J Leukoc Biol"},{"issue":"7","key":"8312_CR110","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/labinvest.2012.54","volume":"92","author":"A Gl\u00e4ssner","year":"2012","unstructured":"Gl\u00e4ssner A, Eisenhardt M, Kr\u00e4mer B, K\u00f6rner C, Coenen M, Sauerbruch T, Spengler U, Nattermann J. NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner. Lab Invest. 2012;92(7):967\u201377.","journal-title":"Lab Invest"},{"issue":"12","key":"8312_CR111","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/17474124.2016.1251309","volume":"10","author":"A El Taghdouini","year":"2016","unstructured":"El Taghdouini A, van Grunsven LA. Epigenetic regulation of hepatic stellate cell activation and liver fibrosis. Expert Rev Gastroenterol Hepatol. 2016;10(12):1397\u2013408.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"7","key":"8312_CR112","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","volume":"36","author":"P Horn","year":"2024","unstructured":"Horn P, Tacke F. Metabolic reprogramming in liver fibrosis. Cell Metab. 2024;36(7):1439\u201355.","journal-title":"Cell Metab"},{"issue":"3","key":"8312_CR113","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/sji.12468","volume":"85","author":"YY Sun","year":"2017","unstructured":"Sun YY, Li XF, Meng XM, Huang C, Zhang L, Li J. Macrophage Phenotype in Liver Injury and Repair. Scand J Immunol. 2017;85(3):166\u201374.","journal-title":"Scand J Immunol"},{"issue":"1","key":"8312_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yexcr.2015.10.017","volume":"347","author":"KL Spiller","year":"2016","unstructured":"Spiller KL, Wrona EA, Romero-Torres S, Pallotta I, Graney PL, Witherel CE, Panicker LM, Feldman RA, Urbanska AM, Santambrogio L, et al. Differential gene expression in human, murine, and cell line-derived macrophages upon polarization. Exp Cell Res. 2016;347(1):1\u201313.","journal-title":"Exp Cell Res"},{"issue":"12","key":"8312_CR115","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"8","author":"DM Mosser","year":"2008","unstructured":"Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958\u201369.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"8312_CR116","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jhep.2025.02.039","volume":"83","author":"A de Zawadzki","year":"2025","unstructured":"de Zawadzki A, Leeming DJ, Sanyal AJ, Anstee QM, Schattenberg JM, Friedman SL, Schuppan D, Karsdal MA. Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis. J Hepatol. 2025;83(1):239\u201357.","journal-title":"J Hepatol"},{"issue":"1","key":"8312_CR117","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, Myung P, Plikus MV, Nie Q. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12(1):1088.","journal-title":"Nat Commun"},{"issue":"6","key":"8312_CR118","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/j.1478-3231.2011.02504.x","volume":"31","author":"F Tacke","year":"2011","unstructured":"Tacke F, Zimmermann HW, Berres ML, Trautwein C, Wasmuth HE. Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases. Liver Int. 2011;31(6):840\u20139.","journal-title":"Liver Int"},{"issue":"4","key":"8312_CR119","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1002\/hep.22443","volume":"48","author":"A Schrage","year":"2008","unstructured":"Schrage A, Wechsung K, Neumann K, Schumann M, Schulzke JD, Engelhardt B, Zeitz M, Hamann A, Klugewitz K. Enhanced T cell transmigration across the murine liver sinusoidal endothelium is mediated by transcytosis and surface presentation of chemokines. Hepatology. 2008;48(4):1262\u201372.","journal-title":"Hepatology"},{"issue":"1","key":"8312_CR120","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4049\/jimmunol.177.1.593","volume":"177","author":"B Eksteen","year":"2006","unstructured":"Eksteen B, Miles A, Curbishley SM, Tselepis C, Grant AJ, Walker LS, Adams DH. Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10. J Immunol. 2006;177(1):593\u2013603.","journal-title":"J Immunol"},{"issue":"10","key":"8312_CR121","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.4049\/jimmunol.1202909","volume":"190","author":"A Wehr","year":"2013","unstructured":"Wehr A, Baeck C, Heymann F, Niemietz PM, Hammerich L, Martin C, Zimmermann HW, Pack O, Gassler N, Hittatiya K, et al. Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. J Immunol. 2013;190(10):5226\u201336.","journal-title":"J Immunol"},{"issue":"11","key":"8312_CR122","doi-asserted-by":"publisher","first-page":"e112327","DOI":"10.1371\/journal.pone.0112327","volume":"9","author":"A Wehr","year":"2014","unstructured":"Wehr A, Baeck C, Ulmer F, Gassler N, Hittatiya K, Luedde T, Neumann UP, Trautwein C, Tacke F. Pharmacological inhibition of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. PLoS ONE. 2014;9(11):e112327.","journal-title":"PLoS ONE"},{"issue":"7854","key":"8312_CR123","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","volume":"592","author":"M Dudek","year":"2021","unstructured":"Dudek M, Pfister D, Donakonda S, Filpe P, Schneider A, Laschinger M, Hartmann D, H\u00fcser N, Meiser P, Bayerl F, et al. Auto-aggressive CXCR6(+) CD8 T cells cause liver immune pathology in NASH. Nature. 2021;592(7854):444\u20139.","journal-title":"Nature"},{"issue":"7854","key":"8312_CR124","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, N\u00fa\u00f1ez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450\u20136.","journal-title":"Nature"},{"issue":"1","key":"8312_CR125","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/s41467-018-04450-y","volume":"9","author":"P Hegde","year":"2018","unstructured":"Hegde P, Weiss E, Paradis V, Wan J, Mabire M, Sukriti S, Rautou PE, Albuquerque M, Picq O, Gupta AC, et al. Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver. Nat Commun. 2018;9(1):2146.","journal-title":"Nat Commun"},{"issue":"6","key":"8312_CR126","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/hep.21419","volume":"44","author":"WI Jeong","year":"2006","unstructured":"Jeong WI, Park O, Radaeva S, Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology. 2006;44(6):1441\u201351.","journal-title":"Hepatology"},{"issue":"1","key":"8312_CR127","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/s41467-023-37453-5","volume":"14","author":"M Mabire","year":"2023","unstructured":"Mabire M, Hegde P, Hammoutene A, Wan J, Ca\u00ebr C, Sayegh RA, Cadoux M, Allaire M, Weiss E, Thibault-Sogorb T, et al. MAIT cell inhibition promotes liver fibrosis regression via macrophage phenotype reprogramming. Nat Commun. 2023;14(1):1830.","journal-title":"Nat Commun"},{"issue":"3","key":"8312_CR128","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nri3623","volume":"14","author":"A Pellicoro","year":"2014","unstructured":"Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014;14(3):181\u201394.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"8312_CR129","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1136\/gutjnl-2016-312473","volume":"66","author":"N Ikenaga","year":"2017","unstructured":"Ikenaga N, Peng ZW, Vaid KA, Liu SB, Yoshida S, Sverdlov DY, Mikels-Vigdal A, Smith V, Schuppan D, Popov YV. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut. 2017;66(9):1697\u2013708.","journal-title":"Gut"},{"issue":"3","key":"8312_CR130","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jhep.2015.04.011","volume":"63","author":"I Mannaerts","year":"2015","unstructured":"Mannaerts I, Leite SB, Verhulst S, Claerhout S, Eysackers N, Thoen LF, Hoorens A, Reynaert H, Halder G, van Grunsven LA. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J Hepatol. 2015;63(3):679\u201388.","journal-title":"J Hepatol"},{"key":"8312_CR131","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12916-014-0159-5","volume":"12","author":"P Byass","year":"2014","unstructured":"Byass P. The global burden of liver disease: a challenge for methods and for public health. BMC Med. 2014;12:159.","journal-title":"BMC Med"},{"issue":"27","key":"8312_CR132","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373(27):2599\u2013607.","journal-title":"N Engl J Med"},{"issue":"4","key":"8312_CR133","first-page":"310","volume":"4","author":"SM Lynch","year":"2016","unstructured":"Lynch SM, Wu GY. Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy. J Clin Transl Hepatol. 2016;4(4):310\u20139.","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"8312_CR134","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149(2):367\u201378. e365; quiz e314\u2013365.","journal-title":"Gastroenterology"},{"issue":"2","key":"8312_CR135","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","volume":"149","author":"G Lassailly","year":"2015","unstructured":"Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, Raverdy V, Leteurtre E, Dharancy S, Louvet A, et al. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Gastroenterology. 2015;149(2):379\u201388. quiz e315\u2013376.","journal-title":"Gastroenterology"},{"issue":"7","key":"8312_CR136","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","volume":"69","author":"R Loomba","year":"2020","unstructured":"Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut. 2020;69(7):1343\u201352.","journal-title":"Gut"},{"issue":"1","key":"8312_CR137","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13244-020-0839-y","volume":"11","author":"AM Osman","year":"2020","unstructured":"Osman AM, El Shimy A, Abd El Aziz MM. 2D shear wave elastography (SWE) performance versus vibration-controlled transient elastography (VCTE\/fibroscan) in the assessment of liver stiffness in chronic hepatitis. Insights Imaging. 2020;11(1):38.","journal-title":"Insights Imaging"},{"issue":"3","key":"8312_CR138","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cgh.2014.09.046","volume":"13","author":"S Singh","year":"2015","unstructured":"Singh S, Venkatesh SK, Wang Z, Miller FH, Motosugi U, Low RN, Hassanein T, Asbach P, Godfrey EM, Yin M, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol. 2015;13(3):440\u2013e451446.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"8312_CR139","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12876-021-01741-5","volume":"21","author":"S Punia","year":"2021","unstructured":"Punia S, Juran BD, Ali AH, Schlicht EM, Moore RM, Sun Z, Lazaridis KN. Evaluation of circulating cell-free DNA in cholestatic liver disease using liver-specific methylation markers. BMC Gastroenterol. 2021;21(1):149.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"8312_CR140","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/gutjnl-2020-322526","volume":"70","author":"X Wang","year":"2021","unstructured":"Wang X, He Y, Mackowiak B, Gao B. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut. 2021;70(4):784\u201395.","journal-title":"Gut"},{"key":"8312_CR141","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","volume":"19","author":"L Jiang","year":"2021","unstructured":"Jiang L, Zhang H, Xiao D, Wei H, Chen Y. Farnesoid X receptor (FXR): Structures and ligands. Comput Struct Biotechnol J. 2021;19:2148\u201359.","journal-title":"Comput Struct Biotechnol J"},{"issue":"9972","key":"8312_CR142","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956\u201365.","journal-title":"Lancet"},{"issue":"5","key":"8312_CR143","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/17446651.2022.2110864","volume":"17","author":"EK Wirth","year":"2022","unstructured":"Wirth EK, Puengel T, Spranger J, Tacke F. Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis. Expert Rev Endocrinol Metab. 2022;17(5):425\u201334.","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"6","key":"8312_CR144","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.jhep.2021.02.012","volume":"74","author":"H Gilgenkrantz","year":"2021","unstructured":"Gilgenkrantz H, Mallat A, Moreau R, Lotersztajn S. Targeting cell-intrinsic metabolism for antifibrotic therapy. J Hepatol. 2021;74(6):1442\u201354.","journal-title":"J Hepatol"},{"key":"8312_CR145","doi-asserted-by":"publisher","first-page":"11808","DOI":"10.3389\/jpps.2023.11808","volume":"26","author":"OS Mohammed","year":"2023","unstructured":"Mohammed OS, Attia HG, Mohamed B, Elbaset MA, Fayed HM. Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches. J Pharm Pharm Sci. 2023;26:11808.","journal-title":"J Pharm Pharm Sci"},{"issue":"4","key":"8312_CR146","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1172\/JCI88845","volume":"127","author":"Y Koyama","year":"2017","unstructured":"Koyama Y, Wang P, Liang S, Iwaisako K, Liu X, Xu J, Zhang M, Sun M, Cong M, Karin D, et al. Mesothelin\/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis. J Clin Invest. 2017;127(4):1254\u201370.","journal-title":"J Clin Invest"},{"issue":"8","key":"8312_CR147","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/cbf.1705","volume":"28","author":"S Vircheva","year":"2010","unstructured":"Vircheva S, Alexandrova A, Georgieva A, Mateeva P, Zamfirova R, Kubera M, Kirkova M. In vivo effects of pentoxifylline on enzyme and non-enzyme antioxidant levels in rat liver after carrageenan-induced paw inflammation. Cell Biochem Funct. 2010;28(8):668\u201372.","journal-title":"Cell Biochem Funct"},{"issue":"5","key":"8312_CR148","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1002\/hep.24544","volume":"54","author":"CO Zein","year":"2011","unstructured":"Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011;54(5):1610\u20139.","journal-title":"Hepatology"},{"issue":"2","key":"8312_CR149","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cyto.2014.11.001","volume":"71","author":"H Ahn","year":"2015","unstructured":"Ahn H, Kim J, Lee MJ, Kim YJ, Cho YW, Lee GS. Methylsulfonylmethane inhibits NLRP3 inflammasome activation. Cytokine. 2015;71(2):223\u201331.","journal-title":"Cytokine"},{"issue":"1","key":"8312_CR150","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1083\/jcb.200903124","volume":"187","author":"M Lamkanfi","year":"2009","unstructured":"Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, Lee WP, Hoffman HM, Dixit VM. Glyburide inhibits the Cryopyrin\/Nalp3 inflammasome. J Cell Biol. 2009;187(1):61\u201370.","journal-title":"J Cell Biol"},{"issue":"16","key":"8312_CR151","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2174\/156802605775009720","volume":"5","author":"SD Linton","year":"2005","unstructured":"Linton SD. Caspase inhibitors: a pharmaceutical industry perspective. Curr Top Med Chem. 2005;5(16):1697\u2013717.","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"8312_CR152","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/apt.15030","volume":"49","author":"M Shiffman","year":"2019","unstructured":"Shiffman M, Freilich B, Vuppalanchi R, Watt K, Chan JL, Spada A, Hagerty DT, Schiff E. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3\/7 activation in subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;49(1):64\u201373.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"8312_CR153","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/hep.22952","volume":"50","author":"E Seki","year":"2009","unstructured":"Seki E, de Minicis S, Inokuchi S, Taura K, Miyai K, van Rooijen N, Schwabe RF, Brenner DA. CCR2 promotes hepatic fibrosis in mice. Hepatology. 2009;50(1):185\u201397.","journal-title":"Hepatology"},{"issue":"7","key":"8312_CR154","first-page":"1858","volume":"119","author":"E Seki","year":"2009","unstructured":"Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, Bursill CA, Llovet JM, Brenner DA, Schwabe RF. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest. 2009;119(7):1858\u201370.","journal-title":"J Clin Invest"},{"issue":"1","key":"8312_CR155","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","volume":"73","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020;73(1):26\u201339.","journal-title":"J Hepatol"},{"issue":"7814","key":"8312_CR156","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, Mansilla-Soto J, Boyer JA, Li X, Giavridis T, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583(7814):127\u201332.","journal-title":"Nature"},{"issue":"7","key":"8312_CR157","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrneph.2016.54","volume":"12","author":"M Edeling","year":"2016","unstructured":"Edeling M, Ragi G, Huang S, Pavenst\u00e4dt H, Susztak K. Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog. Nat Rev Nephrol. 2016;12(7):426\u201339.","journal-title":"Nat Rev Nephrol"},{"key":"8312_CR158","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ebiom.2017.08.016","volume":"23","author":"K Kimura","year":"2017","unstructured":"Kimura K, Ikoma A, Shibakawa M, Shimoda S, Harada K, Saio M, Imamura J, Osawa Y, Kimura M, Nishikawa K, et al. Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP\/\u03b2-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial. EBioMedicine. 2017;23:79\u201387.","journal-title":"EBioMedicine"},{"key":"8312_CR159","doi-asserted-by":"publisher","first-page":"123068","DOI":"10.1016\/j.ijpharm.2023.123068","volume":"641","author":"S Siapoush","year":"2023","unstructured":"Siapoush S, Mousazadeh H, Rezaei R, Hatami B, Mazhari S, Hashemi N, Reza Zali M, Baghaei K. Oral targeted delivery of Imatinib by pH responsive copolymer modulates liver fibrosis in the mice model. Int J Pharm. 2023;641:123068.","journal-title":"Int J Pharm"},{"key":"8312_CR160","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jconrel.2017.09.035","volume":"266","author":"NS El-Mezayen","year":"2017","unstructured":"El-Mezayen NS, El-Hadidy WF, El-Refaie WM, Shalaby TI, Khattab MM, El-Khatib AS. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis. J Control Release. 2017;266:226\u201337.","journal-title":"J Control Release"},{"issue":"2","key":"8312_CR161","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.31236","volume":"72","author":"W Chen","year":"2020","unstructured":"Chen W, Yang A, Jia J, Popov YV, Schuppan D, You H. Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis. Hepatology. 2020;72(2):729\u201341.","journal-title":"Hepatology"},{"issue":"3","key":"8312_CR162","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0165-2478(94)90072-8","volume":"42","author":"KC Jeng","year":"1994","unstructured":"Jeng KC, Frigeri LG, Liu FT. An endogenous lectin, galectin-3 (epsilon BP\/Mac-2), potentiates IL-1 production by human monocytes. Immunol Lett. 1994;42(3):113\u20136.","journal-title":"Immunol Lett"},{"issue":"5","key":"8312_CR163","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","volume":"158","author":"N Chalasani","year":"2020","unstructured":"Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M, Noureddin M, Pyko M, Shiffman M, Sanyal A, et al. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology. 2020;158(5):1334\u2013e13451335.","journal-title":"Gastroenterology"},{"issue":"3","key":"8312_CR164","first-page":"2381","volume":"17","author":"K Han","year":"2019","unstructured":"Han K, Zhang Y, Yang Z. Cilostazol protects rats against alcohol-induced hepatic fibrosis via suppression of TGF-\u03b21\/CTGF activation and the cAMP\/Epac1 pathway. Exp Ther Med. 2019;17(3):2381\u20138.","journal-title":"Exp Ther Med"},{"issue":"11","key":"8312_CR165","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/gut.2007.144550","volume":"57","author":"K Fujita","year":"2008","unstructured":"Fujita K, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H, Iwasaki T, Inamori M, Abe Y, Kobayashi N, et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut. 2008;57(11):1583\u201391.","journal-title":"Gut"},{"issue":"4","key":"8312_CR166","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/hepr.12140","volume":"44","author":"S Saito","year":"2014","unstructured":"Saito S, Hata K, Iwaisako K, Yanagida A, Takeiri M, Tanaka H, Kageyama S, Hirao H, Ikeda K, Asagiri M, et al. Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride-induced liver fibrosis. Hepatol Res. 2014;44(4):460\u201373.","journal-title":"Hepatol Res"},{"issue":"51","key":"8312_CR167","doi-asserted-by":"publisher","first-page":"15713","DOI":"10.1073\/pnas.1522163112","volume":"112","author":"N Ding","year":"2015","unstructured":"Ding N, Hah N, Yu RT, Sherman MH, Benner C, Leblanc M, He M, Liddle C, Downes M, Evans RM. BRD4 is a novel therapeutic target for liver fibrosis. Proc Natl Acad Sci U S A. 2015;112(51):15713\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"8312_CR168","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/hep.510290328","volume":"29","author":"T Niki","year":"1999","unstructured":"Niki T, Rombouts K, De Bleser P, De Smet K, Rogiers V, Schuppan D, Yoshida M, Gabbiani G, Geerts A. A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology. 1999;29(3):858\u201367.","journal-title":"Hepatology"},{"issue":"3","key":"8312_CR169","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.apsb.2023.10.023","volume":"14","author":"R Liu","year":"2024","unstructured":"Liu R, Li Y, Zheng Q, Ding M, Zhou H, Li X. Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead. Acta Pharm Sin B. 2024;14(3):1009\u201329.","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"8312_CR170","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41419-024-06509-9","volume":"15","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Yan J, Huang H, Liu L, Ren L, Hu J, Jiang X, Zheng Y, Xu L, Zhong F, et al. The m(6)A reader IGF2BP2 regulates glycolytic metabolism and mediates histone lactylation to enhance hepatic stellate cell activation and liver fibrosis. Cell Death Dis. 2024;15(3):189.","journal-title":"Cell Death Dis"},{"issue":"1","key":"8312_CR171","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1053\/j.gastro.2020.03.008","volume":"159","author":"M Mejias","year":"2020","unstructured":"Mejias M, Gallego J, Naranjo-Suarez S, Ramirez M, Pell N, Manzano A, Su\u00f1er C, Bartrons R, Mendez R, Fernandez M. CPEB4 Increases Expression of PFKFB3 to Induce Glycolysis and Activate Mouse and Human Hepatic Stellate Cells, Promoting Liver Fibrosis. Gastroenterology. 2020;159(1):273\u201388.","journal-title":"Gastroenterology"},{"issue":"8","key":"8312_CR172","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.cmet.2023.06.013","volume":"35","author":"H Rho","year":"2023","unstructured":"Rho H, Terry AR, Chronis C, Hay N. Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis. Cell Metab. 2023;35(8):1406\u2013e14231408.","journal-title":"Cell Metab"},{"issue":"4","key":"8312_CR173","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cmet.2015.03.006","volume":"21","author":"N Dai","year":"2015","unstructured":"Dai N, Zhao L, Wrighting D, Kr\u00e4mer D, Majithia A, Wang Y, Cracan V, Borges-Rivera D, Mootha VK, Nahrendorf M, et al. IGF2BP2\/IMP2-Deficient mice resist obesity through enhanced translation of Ucp1 mRNA and Other mRNAs encoding mitochondrial proteins. Cell Metab. 2015;21(4):609\u201321.","journal-title":"Cell Metab"},{"issue":"11","key":"8312_CR174","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s42255-021-00488-3","volume":"3","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Peng J, Song J, He J, Jiang M, Wang J, Ma L, Wang Y, Lin M, Wu H, et al. Loss of Hilnc prevents diet-induced hepatic steatosis through binding of IGF2BP2. Nat Metab. 2021;3(11):1569\u201384.","journal-title":"Nat Metab"},{"key":"8312_CR175","doi-asserted-by":"publisher","first-page":"108987","DOI":"10.1016\/j.intimp.2022.108987","volume":"110","author":"Z Xu","year":"2022","unstructured":"Xu Z, He B, Jiang Y, Zhang M, Tian Y, Zhou N, Zhou Y, Chen M, Tang M, Gao J, et al. Igf2bp2 knockdown improves CCl(4)-induced liver fibrosis and TGF-\u03b2-activated mouse hepatic stellate cells by regulating Tgfbr1. Int Immunopharmacol. 2022;110:108987.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"8312_CR176","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s42255-022-00710-w","volume":"5","author":"Z Yang","year":"2023","unstructured":"Yang Z, Yan C, Ma J, Peng P, Ren X, Cai S, Shen X, Wu Y, Zhang S, Wang X, et al. Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma. Nat Metab. 2023;5(1):61\u201379.","journal-title":"Nat Metab"},{"issue":"37","key":"8312_CR177","doi-asserted-by":"publisher","first-page":"5221","DOI":"10.1038\/onc.2017.151","volume":"36","author":"AR Louren\u00e7o","year":"2017","unstructured":"Louren\u00e7o AR, Coffer PJ. A tumor suppressor role for C\/EBP\u03b1 in solid tumors: more than fat and blood. Oncogene. 2017;36(37):5221\u201330.","journal-title":"Oncogene"},{"issue":"24","key":"8312_CR178","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1038\/s41388-018-0126-2","volume":"37","author":"V Reebye","year":"2018","unstructured":"Reebye V, Huang KW, Lin V, Jarvis S, Cutilas P, Dorman S, Ciriello S, Andrikakou P, Voutila J, Saetrom P, et al. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. Oncogene. 2018;37(24):3216\u201328.","journal-title":"Oncogene"},{"issue":"21","key":"8312_CR179","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.1158\/1078-0432.CCR-21-0986","volume":"27","author":"A Hashimoto","year":"2021","unstructured":"Hashimoto A, Sarker D, Reebye V, Jarvis S, Sodergren MH, Kossenkov A, Sanseviero E, Raulf N, Vasara J, Andrikakou P, et al. Upregulation of C\/EBP\u03b1 Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. Clin Cancer Res. 2021;27(21):5961\u201378.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"8312_CR180","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-20-0414","volume":"26","author":"D Sarker","year":"2020","unstructured":"Sarker D, Plummer R, Meyer T, Sodergren MH, Basu B, Chee CE, Huang KW, Palmer DH, Ma YT, Evans TRJ, et al. MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C\/EBP-\u03b1, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. Clin Cancer Res. 2020;26(15):3936\u201346.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"8312_CR181","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1172\/JCI77095","volume":"125","author":"RC Bauer","year":"2015","unstructured":"Bauer RC, Sasaki M, Cohen DM, Cui J, Smith MA, Yenilmez BO, Steger DJ, Rader DJ. Tribbles-1 regulates hepatic lipogenesis through posttranscriptional regulation of C\/EBP\u03b1. J Clin Invest. 2015;125(10):3809\u201318.","journal-title":"J Clin Invest"},{"issue":"11","key":"8312_CR182","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1210\/me.2004-0213","volume":"18","author":"K Matsusue","year":"2004","unstructured":"Matsusue K, Gavrilova O, Lambert G, Brewer HB Jr., Ward JM, Inoue Y, LeRoith D, Gonzalez FJ. Hepatic CCAAT\/enhancer binding protein alpha mediates induction of lipogenesis and regulation of glucose homeostasis in leptin-deficient mice. Mol Endocrinol. 2004;18(11):2751\u201364.","journal-title":"Mol Endocrinol"},{"key":"8312_CR183","doi-asserted-by":"crossref","unstructured":"Zhu C, Kim K, Wang X, Bartolome A, Salomao M, Dongiovanni P, Meroni M, Graham MJ, Yates KP, Diehl AM et al. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Sci Transl Med 2018, 10(468).","DOI":"10.1126\/scitranslmed.aat0344"},{"issue":"11","key":"8312_CR184","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/hep4.1237","volume":"2","author":"O Glass","year":"2018","unstructured":"Glass O, Henao R, Patel K, Guy CD, Gruss HJ, Syn WK, Moylan CA, Streilein R, Hall R, Mae Diehl A, et al. Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2018;2(11):1344\u201355.","journal-title":"Hepatol Commun"},{"issue":"1","key":"8312_CR185","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/nyas.14259","volume":"1465","author":"Z Khajehahmadi","year":"2020","unstructured":"Khajehahmadi Z, Mohagheghi S, Nikeghbalian S, Geramizadeh B, Khodadadi I, Karimi J, Tavilani H. Liver stiffness correlates with serum osteopontin and TAZ expression in human liver cirrhosis. Ann N Y Acad Sci. 2020;1465(1):117\u201331.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"8312_CR186","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12079-020-00554-7","volume":"14","author":"M Honda","year":"2020","unstructured":"Honda M, Kimura C, Uede T, Kon S. Neutralizing antibody against osteopontin attenuates non-alcoholic steatohepatitis in mice. J Cell Commun Signal. 2020;14(2):223\u201332.","journal-title":"J Cell Commun Signal"},{"issue":"1","key":"8312_CR187","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/j.gastro.2023.03.228","volume":"165","author":"H Han","year":"2023","unstructured":"Han H, Ge X, Komakula SSB, Desert R, Das S, Song Z, Chen W, Athavale D, Gaskell H, Lantvit D, et al. Macrophage-derived Osteopontin (SPP1) Protects From Nonalcoholic Steatohepatitis. Gastroenterology. 2023;165(1):201\u201317.","journal-title":"Gastroenterology"},{"key":"8312_CR188","doi-asserted-by":"publisher","first-page":"110108","DOI":"10.1016\/j.biopha.2020.110108","volume":"127","author":"Y Sun","year":"2020","unstructured":"Sun Y, Chen P, Zhai B, Zhang M, Xiang Y, Fang J, Xu S, Gao Y, Chen X, Sui X, et al. The emerging role of ferroptosis in inflammation. Biomed Pharmacother. 2020;127:110108.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"8312_CR189","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1053\/j.gastro.2018.04.032","volume":"155","author":"T Liu","year":"2018","unstructured":"Liu T, Yang H, Fan W, Tu J, Li TWH, Wang J, Shen H, Yang J, Xiong T, Steggerda J, et al. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer. Gastroenterology. 2018;155(2):557\u2013e571514.","journal-title":"Gastroenterology"},{"issue":"9","key":"8312_CR190","doi-asserted-by":"publisher","first-page":"158733","DOI":"10.1016\/j.bbalip.2020.158733","volume":"1865","author":"A Carino","year":"2020","unstructured":"Carino A, Biagioli M, Marchian\u00f2 S, Fiorucci C, Bordoni M, Roselli R, Di Giorgio C, Baldoni M, Ricci P, Monti MC, et al. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865(9):158733.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"1","key":"8312_CR191","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.28251","volume":"63","author":"X Sun","year":"2016","unstructured":"Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, Tang D. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63(1):173\u201384.","journal-title":"Hepatology"},{"issue":"17","key":"8312_CR192","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.scib.2021.01.027","volume":"66","author":"L Xiang","year":"2021","unstructured":"Xiang L, Zeng Q, Liu J, Xiao M, He D, Zhang Q, Xie D, Deng M, Zhu Y, Liu Y, et al. MAFG-AS1\/MAFG positive feedback loop contributes to cisplatin resistance in bladder urothelial carcinoma through antagonistic ferroptosis. Sci Bull (Beijing). 2021;66(17):1773\u201388.","journal-title":"Sci Bull (Beijing)"},{"key":"8312_CR193","doi-asserted-by":"publisher","first-page":"102382","DOI":"10.1016\/j.redox.2022.102382","volume":"54","author":"DH Kim","year":"2022","unstructured":"Kim DH, Choi HI, Park JS, Kim CS, Bae EH, Ma SK, Kim SW. Farnesoid X receptor protects against cisplatin-induced acute kidney injury by regulating the transcription of ferroptosis-related genes. Redox Biol. 2022;54:102382.","journal-title":"Redox Biol"},{"issue":"17","key":"8312_CR194","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.7150\/thno.46001","volume":"10","author":"G Ye","year":"2020","unstructured":"Ye G, Yang Q, Lei X, Zhu X, Li F, He J, Chen H, Ling R, Zhang H, Lin T, et al. Nuclear MYH9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis. Theranostics. 2020;10(17):7545\u201360.","journal-title":"Theranostics"},{"key":"8312_CR195","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.gene.2018.04.048","volume":"664","author":"A Pecci","year":"2018","unstructured":"Pecci A, Ma X, Savoia A, Adelstein RS. MYH9: Structure, functions and role of non-muscle myosin IIA in human disease. Gene. 2018;664:152\u201367.","journal-title":"Gene"},{"issue":"6168","key":"8312_CR196","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.1248627","volume":"343","author":"D Schramek","year":"2014","unstructured":"Schramek D, Sendoel A, Segal JP, Beronja S, Heller E, Oristian D, Reva B, Fuchs E. Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science. 2014;343(6168):309\u201313.","journal-title":"Science"},{"issue":"1","key":"8312_CR197","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41467-021-20904-2","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, Song X, Kuang F, Zhang Q, Xie Y, Kang R, Kroemer G, Tang D. NUPR1 is a critical repressor of ferroptosis. Nat Commun. 2021;12(1):647.","journal-title":"Nat Commun"},{"issue":"1","key":"8312_CR198","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/s41467-021-27452-9","volume":"12","author":"F Yao","year":"2021","unstructured":"Yao F, Deng Y, Zhao Y, Mei Y, Zhang Y, Liu X, Martinez C, Su X, Rosato RR, Teng H, et al. A targetable LIFR-NF-\u03baB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nat Commun. 2021;12(1):7333.","journal-title":"Nat Commun"},{"issue":"5","key":"8312_CR199","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S1097-2765(02)00708-6","volume":"10","author":"DH Goetz","year":"2002","unstructured":"Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 2002;10(5):1033\u201343.","journal-title":"Mol Cell"},{"issue":"4","key":"8312_CR200","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1053\/j.gastro.2023.05.053","volume":"165","author":"S Man","year":"2023","unstructured":"Man S, Deng Y, Ma Y, Fu J, Bao H, Yu C, Lv J, Liu H, Wang B, Li L. Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China. Gastroenterology. 2023;165(4):1025\u201340.","journal-title":"Gastroenterology"},{"issue":"4","key":"8312_CR201","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, Abdelmalek MF, Suzuki A. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology. 2019;70(4):1457\u201369.","journal-title":"Hepatology"},{"key":"8312_CR202","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2017.09.013","volume":"410","author":"C Liu","year":"2017","unstructured":"Liu C, Ren YF, Dong J, Ke MY, Ma F, Monga SPS, Wu R, Lv Y, Zhang XF. Activation of SRY accounts for male-specific hepatocarcinogenesis: Implication in gender disparity of hepatocellular carcinoma. Cancer Lett. 2017;410:20\u201331.","journal-title":"Cancer Lett"},{"issue":"9","key":"8312_CR203","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/stem.2059","volume":"33","author":"S Murakami","year":"2015","unstructured":"Murakami S, Ninomiya W, Sakamoto E, Shibata T, Akiyama H, Tashiro F. SRY and OCT4 Are Required for the Acquisition of Cancer Stem Cell-Like Properties and Are Potential Differentiation Therapy Targets. Stem Cells. 2015;33(9):2652\u201363.","journal-title":"Stem Cells"},{"issue":"23","key":"8312_CR204","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1038\/onc.2013.262","volume":"33","author":"S Murakami","year":"2014","unstructured":"Murakami S, Chishima S, Uemoto H, Sakamoto E, Sato T, Kurabe N, Kawasaki Y, Shibata T, Akiyama H, Tashiro F. The male-specific factor Sry harbors an oncogenic function. Oncogene. 2014;33(23):2978\u201386.","journal-title":"Oncogene"},{"issue":"12","key":"8312_CR205","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41577-023-00894-6","volume":"23","author":"D Tang","year":"2023","unstructured":"Tang D, Kang R, Zeh HJ, Lotze MT. The multifunctional protein HMGB1: 50 years of discovery. Nat Rev Immunol. 2023;23(12):824\u201341.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"8312_CR206","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41556-020-0511-2","volume":"22","author":"F Li","year":"2020","unstructured":"Li F, Huangyang P, Burrows M, Guo K, Riscal R, Godfrey J, Lee KE, Lin N, Lee P, Blair IA, et al. FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome. Nat Cell Biol. 2020;22(6):728\u201339.","journal-title":"Nat Cell Biol"},{"issue":"6","key":"8312_CR207","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1002\/hep.30093","volume":"68","author":"X Ge","year":"2018","unstructured":"Ge X, Arriazu E, Magdaleno F, Antoine DJ, Dela Cruz R, Theise N, Nieto N. High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice. Hepatology. 2018;68(6):2380\u2013404.","journal-title":"Hepatology"},{"issue":"1","key":"8312_CR208","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12964-018-0306-2","volume":"16","author":"BJ Lim","year":"2018","unstructured":"Lim BJ, Lee WK, Lee HW, Lee KS, Kim JK, Chang HY, Lee JI. Selective deletion of hepatocyte platelet-derived growth factor receptor \u03b1 and development of liver fibrosis in mice. Cell Commun Signal. 2018;16(1):93.","journal-title":"Cell Commun Signal"},{"issue":"6669","key":"8312_CR209","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/35799","volume":"391","author":"A Swain","year":"1998","unstructured":"Swain A, Narvaez V, Burgoyne P, Camerino G, Lovell-Badge R. Dax1 antagonizes Sry action in mammalian sex determination. Nature. 1998;391(6669):761\u20137.","journal-title":"Nature"},{"issue":"6","key":"8312_CR210","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jhep.2024.01.036","volume":"80","author":"XN Wu","year":"2024","unstructured":"Wu XN, Wang MZ, Zhang N, Zhang W, Dong J, Ke MY, Xiang JX, Ma F, Xue F, Hou JJ, et al. Sex-determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology. J Hepatol. 2024;80(6):928\u201340.","journal-title":"J Hepatol"},{"issue":"1","key":"8312_CR211","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41421-025-00783-3","volume":"11","author":"T Li","year":"2025","unstructured":"Li T, Wang G, Zhao H, Liu F, Deng Z, Chen D, Zhou X, Cao Y, Fu W, Zhang H, et al. Estrogen receptor 1 signaling in hepatic stellate cells designates resistance to liver fibrosis. Cell Discov. 2025;11(1):37.","journal-title":"Cell Discov"},{"issue":"6","key":"8312_CR212","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/1061186X.2022.2044485","volume":"30","author":"L Zhou","year":"2022","unstructured":"Zhou L, Li Y, Liang Q, Liu J, Liu Y. Combination therapy based on targeted nano drug co-delivery systems for liver fibrosis treatment: a review. J Drug Target. 2022;30(6):577\u201388.","journal-title":"J Drug Target"},{"issue":"15","key":"8312_CR213","doi-asserted-by":"publisher","first-page":"e2409038","DOI":"10.1002\/smll.202409038","volume":"21","author":"B Li","year":"2025","unstructured":"Li B, Bao J, Huang Y, Liu J, Yan X, Zou Q. Dual-Integrin-Targeted Supramolecular Peptide Nanoarchitectonics for Enhanced Hepatic Delivery and Antifibrotic Therapy. Small. 2025;21(15):e2409038.","journal-title":"Small"},{"issue":"5","key":"8312_CR214","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/hep.510290526","volume":"29","author":"L Beljaars","year":"1999","unstructured":"Beljaars L, Molema G, Weert B, Bonnema H, Olinga P, Groothuis GM, Meijer DK, Poelstra K. Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology. 1999;29(5):1486\u201393.","journal-title":"Hepatology"},{"key":"8312_CR215","doi-asserted-by":"publisher","first-page":"172913","DOI":"10.1016\/j.ejphar.2020.172913","volume":"870","author":"M Ocker","year":"2020","unstructured":"Ocker M. Challenges and opportunities in drug development for nonalcoholic steatohepatitis. Eur J Pharmacol. 2020;870:172913.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"8312_CR216","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","volume":"44","author":"G D\u2019Amico","year":"2006","unstructured":"D\u2019Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217\u201331.","journal-title":"J Hepatol"},{"key":"8312_CR217","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","volume":"65","author":"M Parola","year":"2019","unstructured":"Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37\u201355.","journal-title":"Mol Aspects Med"},{"issue":"6","key":"8312_CR218","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"XM Meng","year":"2016","unstructured":"Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-\u03b2: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325\u201338.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"8312_CR219","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","volume":"22","author":"QM Anstee","year":"2024","unstructured":"Anstee QM, Neuschwander-Tetri BA, Wai-Sun Wong V, Abdelmalek MF, Rodriguez-Araujo G, Landgren H, Park GS, Bedossa P, Alkhouri N, Tacke F, et al. Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study. Clin Gastroenterol Hepatol. 2024;22(1):124\u2013e134121.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"8312_CR220","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","volume":"155","author":"SA Harrison","year":"2018","unstructured":"Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, Lawitz EJ, Rockey DC, Schall RA, Jia C, et al. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology. 2018;155(4):1140\u201353.","journal-title":"Gastroenterology"},{"issue":"6","key":"8312_CR221","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Resmetirom: First Approval. Drugs. 2024;84(6):729\u201335.","journal-title":"Drugs"},{"issue":"10","key":"8312_CR222","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1021\/jm4019299","volume":"57","author":"MJ Kelly","year":"2014","unstructured":"Kelly MJ, Pietranico-Cole S, Larigan JD, Haynes NE, Reynolds CH, Scott N, Vermeulen J, Dvorozniak M, Conde-Knape K, Huang KS, et al. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor \u03b2 agonist in clinical trials for the treatment of dyslipidemia. J Med Chem. 2014;57(10):3912\u201323.","journal-title":"J Med Chem"},{"issue":"11","key":"8312_CR223","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, Alkhouri N, Bashir MR. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29(11):2919\u201328.","journal-title":"Nat Med"},{"issue":"48","key":"8312_CR224","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.3748\/wjg.v30.i48.5205","volume":"30","author":"A Singh","year":"2024","unstructured":"Singh A, Sohal A, Batta A. GLP-1, GIP\/GLP-1, and GCGR\/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. World J Gastroenterol. 2024;30(48):5205\u201311.","journal-title":"World J Gastroenterol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08312-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08312-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08312-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:03:29Z","timestamp":1784693009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08312-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":224,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8312"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08312-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors consent to publication of the present manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"941"}}